Bernstein Harold 4

What Happened

• Harold Bernstein, President of R&D and Chief Medical Officer at Maze Therapeutics, exercised options and sold company stock on March 20, 2026. The filing shows he acquired 15,000 shares by exercising/options conversion at $10.42 per share (cost $156,300) and sold a total of 15,000 shares in three open‑market transactions for aggregate proceeds of $736,440. The Form 4 also reports a separate derivative conversion/settlement of 15,000 shares shown with a $0.00 price and $0 proceeds.

Key Details

• Date of transactions: March 20, 2026.
• Exercise/acquisition: 15,000 shares at $10.42 each — $156,300 total.
• Sales (open market), weighted average prices and proceeds:
  • 6,161 shares at $48.20 (weighted) — $296,977 (prices ranged $47.77–$48.75).
  • 3,795 shares at $49.32 (weighted) — $187,169 (prices ranged $48.78–$49.77).
  • 5,044 shares at $50.02 (weighted) — $252,294 (prices ranged $49.79–$50.52).
  • Total reported sales proceeds: $736,440.
• Additional derivative entry: 15,000 shares reported as exercised/converted and disposed at $0.00 (no cash proceeds reported).
• Plan/footnotes: Transactions were effected under a Rule 10b5‑1 trading plan adopted Sept 29, 2025. The filing includes weighted‑average price ranges and a vesting schedule note for the underlying award.
• Shares owned after the transaction: Not disclosed in the provided excerpt of the Form 4.
• Timeliness: Filing date and report period are both Mar 20, 2026 — appears timely (not marked late).

Context

• This filing shows an exercise of options and same‑day market sales of the same number of shares — a common pattern when executives exercise stock options and sell shares to cover costs or diversify. The separate $0.00 derivative entry likely reflects internal conversion/settlement mechanics reported on the Form 4 (not a cash sale).
• The trades were executed under a pre‑arranged 10b5‑1 plan, which is intended to permit scheduled trading regardless of later company developments; such plans are common and reduce the likelihood that these individual sales signal new insider sentiment.